SCHEMBL769880

SCHEMBL769880

CC1CCCN(C(=O)CC(=O)N2CCC3CCCC=C3C2)C1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 2/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 3/20 0.44
MEN1 O00255 3/20 0.44
MAPT P10636 1/20 0.44
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GRM5 P41594 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771940 0.93 KMT2A (0.50) ALDH1A1LMNASMN1; SMN2HPGDKMT2A
SCHEMBL770549 0.91 KMT2A (0.54) ALDH1A1LMNASMN1; SMN2HPGDKMT2A
SCHEMBL771903 0.91 KMT2A (0.54) ALDH1A1LMNASMN1; SMN2HPGDKMT2A
SCHEMBL770293 0.89 KMT2A (0.37) ALDH1A1LMNAHPGDKMT2APOLB
SCHEMBL770075 0.88 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2HPGDKMT2A
SCHEMBL771057 0.86 RECQL (0.42) ALDH1A1LMNASMN1; SMN2HPGDKMT2A
SCHEMBL770397 0.85 ALDH1A1 (0.36) ALDH1A1LMNASMN1; SMN2HPGDKMT2A
SCHEMBL769770 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HPGDKMT2ATDP1
SCHEMBL770610 0.82 POLB (0.41) ALDH1A1SMN1; SMN2HPGDKMT2APOLB
SCHEMBL770894 0.81 KDM1A (0.39) ALDH1A1LMNASMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885LMNA 3155/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885LMNA 3116/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.